Business
Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer\nPR Newswire\nORLANDO, Fla., Aug. 23, 2016\n\n\n\nORLANDO, Fla., Aug. 23, 2016 /PRNewswire-USNewswire/ -- Immune Therapeutics, Inc. (OTCQB-IMUN) (\"IMUN\"), headquartered in Orlando, Florida, is a clinical-stage biopharmaceutical company involved in the commercialization, manufacturing, distribution and marketing of its novel immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system. \n\nIMUN, in conjunction with the College of Medicine Malawi, has initiated a clinical study with LDN for the prevention of cervical cancer. This is an open-label, multicenter study designed to determine the safety and acceptability of a single-visit approach to cervical cancer prevention in patients. Using a single-visit approach to prevent cervical cancer, women will be examined through visual inspection of the cervix with acetic acid wash (VIA) and, if tests results are positive, patients will be offered immediate cryotherapy of the precancerous lesion. The secondary objectives are to determine life extension, to improve the immune system of immune comprised patients by starting treatment with LDN.\n\nThe Brewer Foundation in partnership with IMUN arranged both the funding for the trial and the donation of the Wallach LL100 Cryosurgical system necessary to run the trial and treat patients. \n\n\"The joint goal of this ever-important initiative is to empower the people of Malawi and to provide affordable health solutions to those most vulnerable. With this trial, we, with IMUN and its subsidiaries, hope to combat cervical cancer and immediately start saving lives in our ongoing initiative to improve global health,\" s...